GlassScriptPhysician profile
Stephen F Lemons
NPI 1366403263
$11,472.62
in general payments reported to CMS, 2019-2025
63 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $1,195 · 2021: $1,884 · 2022: $1,661 · 2023: $1,381 · 2024: $2,048 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,637 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,636.67 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,425.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,156.76 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $920.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $860.08 | 2019-2025 | |
| Novo Nordisk INC | $693.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $635.33 | 2019-2025 | |
| Astellas Pharma US INC | $492.31 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.27 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $356.01 | 2021-2025 | |
| Amarin Pharma, INC. | $305.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $297.37 | 2020-2023 | Belsomra, Steglujan, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.63 | 2019-2024 | Jardiance, Ofev |
| Vanda Pharmaceuticals INC. | $258.25 | 2024-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $254.87 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Zyla Life Sciences, INC. | $221.86 | 2019 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.